Capital One National Association’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Capital One National Association’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$821K	Buy	+14,709	New	+$767K	0.11%	167

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Capital One National Association's PBE Position: Q4 2019 in Review

Capital One National Association opened a new position in Invesco Biotechnology & Genome ETF (PBE) in Q4 2019: 14,709 shares worth $821K. The stake represents 0.11% of the portfolio and ranks #167 among its holdings.

78 funds tracked by Wall St. Rank hold PBE as of Q4 2019.

Capital One National Association held 14,709 shares of Invesco Biotechnology & Genome ETF worth $821K as of Q4 2019.
Invesco Biotechnology & Genome ETF was a new Capital One National Association position in Q4 2019.
Invesco Biotechnology & Genome ETF made up 0.11% of Capital One National Association's portfolio in Q4 2019, its #167 holding.
78 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2019.

Based on Capital One National Association's 13F filing for Q4 2019, filed 11 Feb 2020.